Anlon Healthcare IPO to Open on August 26, 2025: Check Issue Size, Price Band and Key Dates

22 August 2025
2 min read
Anlon Healthcare IPO to Open on August 26, 2025: Check Issue Size, Price Band and Key Dates
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

Anlon Healthcare Ltd is launching its Initial Public Offer (IPO) on August 26, 2025 for public subscription. The company specialises in the production of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

The bidding window for the Anlon Healthcare IPO will be open till August 29, 2025 and the allotment process is expected to be finalised on September 1, 2025. The shares of Anlon Healthcare Ltd will be listed on both the BSE and NSE websites with a tentative listing date fixed as September 3, 2025. 

Anlon Healthcare IPO Details

Anlon Healthcare IPO is a book build issue of ₹121.03 crores. The issue is entirely a fresh issue of 1.33 crore shares.

The IPO price band is set at ₹86 - ₹91 per share. The lot size for an application is 164. And the minimum investment required by an retail investor is ₹14,104 (148 shares).

Interactive Financial Services Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.

Utilisation of Proceeds

The company will utilise the net proceeds from the issue towards the following purposes:

  • Funding capital expenditure requirements for Proposed Expansion.
  • Full or part repayment and/or prepayment of certain outstanding secured borrowing (term loan) availed by the Company.
  • Funding the working capital requirements of the Company.
  • General corporate purposes.

Check out newly Listed IPOs on BSE and NSE.

Anlon Healthcare Ltd - Business Overview

Anlon Healthcare Limited, incorporated in 2013 and based in Rajkot, is a chemical manufacturing company specializing in high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its offerings include pharmaceutical formulations, nutraceuticals, personal care, and veterinary products. The company has 65 commercial products, with several more under pilot and lab stages.

Financially, the company reported a revenue of ₹120.46 crore in FY25, up from ₹66.69 crore in FY24, while, Profit After Tax (PAT) increased to ₹20.52 crore. Total assets rose to ₹181.30 crore, reflecting expansion and improved operational efficiency.

Explore other Upcoming IPOs on BSE and NSE.

 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here.

Do you like this edition?